The time course of serum C-reactive protein is more predictive of mortality than its baseline level in peritoneal dialysis patients

Peritoneal Dialysis International

Volumn 25, Issue 3, 2005, Pages 256-268

  Ateş, Kenan ^a,c   Ateş, Aşkin ^b   Ekmekçi, Yakup ^a   Nergizoglu, Gökhan ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b ANKARA NUMUNE HOSPITAL   (Turkey)

^c NONE   (Turkey)

Author keywords

Baseline CRP level; End stage renal disease; Left ventricular hypertrophy; Mortality; Serum C reactive protein (CRP); Time averaged CRP level

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; UREA;

ACUTE PHASE RESPONSE; ADULT; AGE; AGED; ARTICLE; BIOCHEMISTRY; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; COMORBIDITY; CONCENTRATION (PARAMETERS); CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DIALYSATE; DISEASE COURSE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; INTERMETHOD COMPARISON; KIDNEY DISEASE; KIDNEY FUNCTION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT MONITORING; PERITONEAL DIALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN ANALYSIS; REGRESSION ANALYSIS; SURVIVAL; SYMPTOM; TIME;

EID: 19444388151     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080502500309     Document Type: Article

References (43)

1. United States Renal Data System. USRDS 1997 Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1999.
2. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal failure. Am J Kidney Dis 1998; 32(Suppl 3):112-19.
3. Nolph KD, Cutler SJ, Steinberg SM, Novak JM, Hirshman GH. Factors associated with morbidity and mortality among patients on CAPD. ASAIO Trans 1987; 33:54-65.
4. Avram MM, Goldwasser P, Erroa M, Fein PA. Predictors of survival in continuous ambulatory peritoneal dialysis: the importance of prealbumin and other nutritional and metabolic markers. Am J Kidney Dis 1994; 23:91-8.
5. Struijk DG, Krediet RT, Koomen GCM, Boeschoten EW, Arisz L. The effect of serum albumin at the start of continuous ambulatory peritoneal dialysis treatment on patient survival. Perit Dial Int 1994; 14:121-6.
6. Churchill DN, Taylor DW, Keshaviah PR, the Canada-USA (CANUSA) Peritoneal Dialysis Study Group. Adequacy of dialysis and nutrition in continuous ambulatory peritoneal dialysis patients. J Am Soc Nephrol 1996; 7:198-207.
7. Wang T, Heimbürger O, Waniewski J, Bergström J, Lindholm B. Increased peritoneal permeability is associated with decreased fluid and small-solute removal and higher mortality in CAPD patients. Nephrol Dial Transplant 1998; 13:1242-9.
8. Jager KJ, Merkus MP, Dekker FW, Boeschoten EW, Tijssen JGP, Stevens P, et al. Mortality and technique failure in patients starting chronic peritoneal dialysis: results of the Netherlands Cooperative Study on the Adequacy of Dialysis. Kidney Int 1999; 55:1476-85.
9. Maiorca R, Brunori G, Zubani R, Cancarini GC, Manili L, Camerini C, et al. Predictive value of dialysis adequacy and nutritional indices for mortality and morbidity in CAPD and HD patients. A longitudinal study. Nephrol Dial Transplant 1995; 10:2295-305.
10. Ates K, Nergizoglu G, Keven K, Sen A, Kutlay S, Ertürk S, et al. Effect of fluid and sodium removal on mortality in peritoneal dialysis patients. Kidney Int 2001; 60:767-76.
11. Bergström J, Heimbürger O, Lindholm B, Qureshi AR. Elevated serum C-reactive protein is a strong predictor of increased mortality and low serum albumin in hemodialysis (HD) patients [Abstract]. J Am Soc Nephrol 1995; 6:573.
12. Noh H, Lee SW, Kang SW, Shin SK, Choi KH, Lee HY, et al. Serum C-reactive protein: a predictor of mortality in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1998; 18:387-94.
13. Iseki K, Tozawa M, Yoshi S, Fukiyama K. Serum C-reactive protein and risk of death in chronic dialysis patients. Nephrol Dial Transplant 1999; 14:1956-60.
14. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648-58.
15. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000; 35:469-76.
16. Haubitz M, Brunkhorst R. C-reactive protein and chronic Chlamydia pneumoniae infection - long-term predictors for cardiovascular disease and survival in patients on peritoneal dialysis. Nephrol Dial Transplant 2001; 16:809-15.
17. Wang AY, Woo J, Lam CW, Wang M, Sea MM, Lui SF, et al. Is a single time point C-reactive protein predictive of outcome in peritoneal dialysis patients? J Am Soc Nephrol 2003; 14:1871-9.
18. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994; 331:417-24.
19. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9.
20. Stenvinkel P, Heimbürger O, Paultre F, Diczfalusy U, Wang T, Berglund L, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55:1899-911.
21. Arici M, Walls J. End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link? Kidney Int 2001; 59:407-14.
22. Lowrie EG. Acute-phase inflammatory process contributes to malnutrition, anemia, and possibly other abnormalities in dialysis patients. Am J Kidney Dis 1998; 32(Suppl 4): S105-12.
23. Pecoits-Filho R, Lindholm B, Stenvinkel P. The malnutrition, inflammation, and atherosclerosis (MIA) syndrome - the heart of the matter. Nephrol Dial Transplant 2002; 17(Suppl 11):28-31.
24. Kaysen GA, Dubin JA, Müller HG, Rosales LM, Levin NW, and The HEMO Study Group. The acute-phase response varies with time and predicts serum albumin levels in hemodialysis patients. Kidney Int 2000; 58:346-52.
25. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373-83.
26. Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916; 16:863-71.
27. Sahn DJ, De Maria A, Kisslo J, Weyman A. The Committee on M-Mode Standardization of the American Society of Echocardiography. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58:1072-83.
28. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57:450-8.
29. Savage DD, Garrison RJ, Kannel WB, Levy D, Anderson SJ, Stokes J, et al. The spectrum of left ventricular hypertrophy in a general population sample: the Framingham Study. Circulation 1987; 75(Suppl I):I26-33.
30. Twardowski ZJ, Nolph KD, Khanna R, Prowant BF, Ryan LP, Moore HL, et al. Peritoneal equilibration test. Perit Dial Bull 1987; 7:138-47.
31. Watson PE, Watson ID, Batt RD. Total body water volumes for adult males and females estimated from simple anthropometric measurements. Am J Clin Nutr 1980; 33:27-39.
32. Bergström J, Furst P, Alvestrand A, Lindholm B. Protein and energy intake, nitrogen balance and nitrogen losses in patients treated with continuous ambulatory peritoneal dialysis. Kidney Int 1993; 44:1048-57.
33. Ikizler TA, Wingard RL, Harvell J, Shyr Y, Hakim RM. Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: a prospective study. Kidney Int 1999; 55:1945-51.
34. London GM, Drüeke TB. Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int 1997; 51:1678-95.
35. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340:115-26.
36. Muhlestein JB. Chronic infection and coronary artery disease. Med Clin North Am 2000; 84:123-48.
37. Lagrand WK, Niessen HW, Wolbink GJ, Jaspars LH, Visser CA, Verheugt FW, et al. C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation 1997; 95:97-103.
38. Bhakdi S, Torzewski M, Klouche M, Hemmes M. Binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol 1999; 19: 2348-54.
39. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993; 82: 513-20.
40. Gunnell J, Yeun JY, Depner TA, Kaysen GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 1999; 33:63-72.
41. Vigushin DM, Pepys MB, Hawkins PN. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein health and disease. J Clin Invest 1993; 91:1351-7.
42. Fine A. Relevance of C-reactive protein levels in peritoneal dialysis patients. Kidney Int 2002; 61:615-20.
43. Haubitz M, Brunkhorst R, Wrenger E, Froese P, Schulze M, Koch KM. Chronic induction of C-reactive protein by hemodialysis, but not by peritoneal dialysis therapy. Perit Dial Int 1996; 16:158-62.